Latest results FY2025 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 19191,665 employeesWebsite
A leading Japanese manufacturer of OTC pharmaceuticals and consumer goods, specializing in innovative products that fulfill niche consumer needs across healthcare and household categories.
Business segments (share of revenue)
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Domestic Market Business | 72% | ¥118.1B | ¥14.0B | 11.8% |
| International Business Operations | 28% | ¥47.0B | ¥810M | 1.7% |
Close (Oct 30, 2026)
¥7,089+39.5% (1Y)
Kobayashi +39.5% over 1Y, 28.0pt above the industry average (23 companies, +11.5%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥165.7B | ¥14.9B | ¥3.7B | ¥275.3B | +0.1% |
| 2024FY | ¥165.6B | ¥24.9B | ¥10.1B | ¥265.4B | -4.5% |
| 2023FY | ¥173.5B | ¥25.8B | ¥20.3B | ¥267.5B | +4.3% |
| 2022FY | ¥166.3B | ¥26.7B | ¥20.0B | ¥255.8B | +7.1% |
| 2021FY | ¥155.3B | ¥26.1B | ¥19.7B | ¥252.6B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Mar 2025)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
